deferoxamine has been researched along with cardiovascular agents in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collis, CS; Davies, MJ; Rice-Evans, C | 1 |
| Buc Calderon, PM; Evdokimova, E; Martos, M | 1 |
| Chang, JS; Peng, CT; Tsai, CH; Wu, KH | 1 |
3 other study(ies) available for deferoxamine and cardiovascular agents
| Article | Year |
|---|---|
Comparison of N-methyl hexanoylhydroxamic acid, a novel antioxidant, with desferrioxamine and N-acetyl cysteine against reperfusion-induced dysfunctions in isolated rat heart.
Topics: Acetylcysteine; Animals; Antioxidants; Cardiovascular Agents; Deferoxamine; Heart; Heart Rate; Hydroxamic Acids; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Perfusion; Rats; Rats, Wistar; Ventricular Function, Left; Ventricular Pressure | 1993 |
Protective effect of fructose on survival and metabolic capacities of hepatocytes kept overnight under cold hypoxia before normothermic reoxygenation.
Topics: Adenosine; Animals; Cardiovascular Agents; Cell Hypoxia; Cell Survival; Deferoxamine; Fructose; Gluconeogenesis; L-Lactate Dehydrogenase; Liver; Male; Rats; Rats, Wistar; Siderophores; Temperature; Tissue Preservation | 1997 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Heart Failure; Hepatitis C, Chronic; Humans; Hypogonadism; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Osteoporosis; Pyridones; Splenectomy; Transfusion Reaction; Tricuspid Valve Insufficiency | 2004 |